Skye Bioscience

Historical price data

Skye Bioscience is a clinical-stage biotech focused on developing next-generation therapeutics for obesity and metabolic diseases by selectively inhibiting the peripheral cannabinoid 1 (CB1) receptor. Its core achievement is the advancement of nimacimab, a potentially first-in-class monoclonal antibody, which demonstrated positive combination data with semaglutide in a Phase 2a trial and recently entered a strategic collaboration with Halozyme. The company's strategy is to clinically validate this differentiated, non-GLP-1 mechanism that aims to improve metabolic health, preserve muscle mass, and offer durable weight loss, positioning it as a complementary therapy in the expansive obesity landscape.

Platform focused on developing peripherally-restricted inhibitors of the cannabinoid 1 (CB1) receptor, primarily using monoclonal antibody technology, to unlock metabolic benefits while avoiding central nervous system side effects.

Skye competes in the crowded obesity market dominated by GLP-1 agonists from Eli Lilly and Novo Nordisk. Its direct competition consists of other companies developing non-GLP-1 mechanisms, including other peripheral CB1 inhibitors (small molecules). Skye's monoclonal antibody approach and Halozyme collaboration are key differentiators, but it must prove clinical superiority or a unique benefit profile to secure a market position.